Study Design, Feasibility Issues Going To Pediatric Oncology Advisory Subcommittee
This article was originally published in The Pink Sheet Daily
Executive Summary
Four products to be considered at Nov. 1 meeting, including whether one therapy can advance a cure rate that hasn't changed in 20 years.
You may also be interested in...
Votrient Combination Therapy Still An Option In Pediatrics, Subcommittee Tells GSK
The company reported difficulties combining the drug with other chemotherapies in adults, but FDA's pediatric oncology subcommittee says that may not be the case in children.
Votrient Combination Therapy Still An Option In Pediatrics, Subcommittee Tells GSK
The company reported difficulties combining the drug with other chemotherapies in adults, but FDA's pediatric oncology subcommittee says that may not be the case in children.